Affiliations 

  • 1 Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, UCSI University, 1, Jalan Menera Gading, Cheras, 56000, Kuala Lumpur, Malaysia. [email protected]
  • 2 Tesco Pharmacy, Gallagher Retail Park, Scunthorpe, DN15 8GR, UK
Int J Clin Pharm, 2016 Oct;38(5):1075-9.
PMID: 27586371 DOI: 10.1007/s11096-016-0372-8

Abstract

Background Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs. Objective To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia. Setting Oncology formulary in Malaysia. Method The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents). Main outcome measures Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period. Results Oncology drugs having a shorter post-approval use period (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.